Info From IRISYS

IRISYS receives Exceptional rating as contractor from NCI

八月 13th, 2018
We are happy to receive our new Contractor Performance …

Continue Reading


The Future Of Drug Development in China

七月 19th, 2018
IRISYS Chairman, CEO & Founder Dr. Gerald Yakatan h …

Continue Reading


Meeting: Dispelling the Mystique of Pre-IND Meetings

七月 9th, 2018
Biocom Regulatory Affairs Committee (RAC) IN-PERSON MEE …

Continue Reading


China’s CROs Make Connection in S.D.

六月 11th, 2018
We had the honor to be featured on this week’s is …

Continue Reading


Proprietary Liposomal Formulation Platform Technology Partnership Opportunity

六月 6th, 2018
To meet the demand for developing chemotherapies with d …

Continue Reading


How New Drugs Are Made

五月 2nd, 2018
General Information This infographic describes the drug …

Continue Reading


Event: FDA Regulatory Strategies and CMC Considerations

三月 13th, 2018
March 21st, 2018 5:00 pm to 7:00 pm 6828 Nancy Ridge Dr …

Continue Reading


The Yakatan Rules for Pharma R&D Efficiency #2

十一月 2nd, 2017
 Welcome to The Yakatan Rules blog, which shares the op …

Continue Reading


Z-Endoxifen manufactured for the National Cancer Institute

九月 11th, 2017
IriSys is privileged to have manufactured capsules of Z …

Continue Reading


The Yakatan Rules for Pharma R&D Efficiency #1

九月 4th, 2017
“…a man should share the passion and action of his time …

Continue Reading